

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau188mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08 "Ask CAS" for self-help around the clock
NEWS	3	Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09 ZDB will be removed from STN
NEWS	5	Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03 New e-mail delivery for search results now available
NEWS	10	Jun 10 MEDLINE Reload
NEWS	11	Jun 10 PCTFULL has been reloaded
NEWS	12	Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29 Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30 NETFIRST to be removed from STN
NEWS	16	Aug 08 CANCERLIT reload
NEWS	17	Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08 NTIS has been reloaded and enhanced
NEWS	19	Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26 Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03 JAPIO has been reloaded and enhanced
NEWS	24	Sep 16 Experimental properties added to the REGISTRY file
NEWS	25	Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS	EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS	HOURS	STN Operating Hours Plus Help Desk Availability
NEWS	INTER	General Internet Information
NEWS	LOGIN	Welcome Banner and News Items
NEWS	PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS	WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

BEST AVAILABLE COPY

FILE 'HOME' ENTERED AT 15:34:48 ON 11 OCT 2002

=> file ca,biosis, medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CA' ENTERED AT 15:35:01 ON 11 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:35:01 ON 11 OCT 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 15:35:01 ON 11 OCT 2002

=> s diabetic cardiomyopathy?

L1 1065 DIABETIC CARDIOMYOPATHY?

=> s GLP-1?

TERM '1?' EXCEEDED TRUNCATION LIMITS - SEARCH ENDED

<-----User Break----->

u

SEARCH ENDED BY USER

You have entered a truncated stem which occurs in too many terms.

Make the stem longer and try again. For example, if your original

term was 'degr?' to search for variations and the abbreviation for

'degradation', you could replace it with the expression '(degrdn OR

degrad?)'. If your search term was numeric, e.g., 'C>5', reduce the

size of the range.

=> s GLP-1

L2 3549 GLP-1

=> d his

(FILE 'HOME' ENTERED AT 15:34:48 ON 11 OCT 2002)

FILE 'CA, BIOSIS, MEDLINE' ENTERED AT 15:35:01 ON 11 OCT 2002

L1 1065 S DIABETIC CARDIOMYOPATHY?

L2 3549 S GLP-1

=> s l1 and l2

L3 1 L1 AND L2

=> d

L3 ANSWER 1 OF 1 CA COPYRIGHT 2002 ACS

AN 136:350560 CA

TI Treatment of hibernating myocardium and **diabetic cardiomyopathy** with a GLP-1 peptide

IN Ehlers, Mario

PA Coolidge, Thomas R., USA

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```

-----
PI   WO 2002034285      A2    20020502      WO 2001-US32559  20011022
      W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
          CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
          GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
          LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
          PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
          US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
      RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
          DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
          BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
      US 2002146405      A1    20021010      US 2001-982978  20011022
PRAI US 2000-241834P    P      20001020
      US 2000-242139P    P      20001023
      US 2000-245234P    P      20001103

```

=> d ab,bib

L3 ANSWER 1 OF 1 CA COPYRIGHT 2002 ACS

AB Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinephrine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. **GLP-1** reduces plasma norepinephrine levels, and it thus is useful in a method of treating hibernating myocardium or **diabetic cardiomyopathy**.

AN 136:350560 CA

TI Treatment of hibernating myocardium and **diabetic cardiomyopathy** with a **GLP-1** peptide

IN Ehlers, Mario

PA Coolidge, Thomas R., USA

SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034285	A2	20020502	WO 2001-US32559	20011022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002146405	A1	20021010	US 2001-982978	20011022
PRAI	US 2000-241834P	P	20001020		
	US 2000-242139P	P	20001023		
	US 2000-245234P	P	20001103		

WEST☐ Generate Collection

L6: Entry 5 of 6

File: USPT

Aug 21, 2001

DOCUMENT-IDENTIFIER: US 6277819 B1

TITLE: Use of GLP-1 or analogs in treatment of myocardial infarctionAbstract Text (1):

This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

Brief Summary Text (6):

Factors responsible for the poor prognosis among diabetic patients with acute myocardial infarction may act before, during, or after the acute event. They include diffuse coronary atheromatosis, with more advanced and widespread coronary artery disease, which, together with a possible diabetic cardiomyopathy, may contribute to a high prevalence of congestive heart failure. Autonomic neuropathy with impaired pain perception and increased resting heart rate variability may also be of importance. A coronary thrombus is an essential part of an evolving infarction, and notably, platelet activity, coagulation, and fibrinolytic functions have been found to be disturbed in diabetic patients [Davis G., et al., New England J. Med., 322:1769-1774 (1990)].

Brief Summary Text (11):

The incretin hormone, glucagon-like peptide 1, abbreviated as GLP-1, is processed from proglucagon in the gut and enhances nutrient-induced insulin release [Krcymann B., et al., Lancet 2:1300-1303 (1987)]. Various truncated forms of GLP-1, are known to stimulate insulin secretion (insulinotropic action) and cAMP formation [see, e.g., Mojsov, S., Int. J. Peptide Protein Research, 40:333-343 (1992)]. A relationship between various in vitro laboratory experiments and mammalian, especially human, insulinotropic responses to exogenous administration of GLP-1, GLP-1(7-36) amide, and GLP-1(7-37) acid has been established [see, e.g., Nauck, M. A., et al., Diabetologia, 36:741-744 (1993); Gutniak, M., et al., New England J. of Medicine, 326(20):1316-1322 (1992); Nauck, M. A., et al., J. Clin. Invest., 91:301-307 (1993); and Thorens, B., et al., Diabetes, 42:1219-1225 (1993)]. GLP-1(7-36) amide exerts a pronounced antidiabetogenic effect in insulin-dependent diabetics by stimulating insulin sensitivity and by enhancing glucose-induced insulin release at physiological concentrations [Gutniak M., et al., New England J. Med. 326:1316-1322 (1992)]. When administered to non-insulin dependent diabetics, GLP-1(7-36) amide stimulates insulin release, lowers glucagon secretion, inhibits gastric emptying and enhances glucose utilization [Nauck, 1993; Gutniak, 1992; Nauck, 1993].

Brief Summary Text (12):

The use of GLP-1 type molecules for prolonged therapy of diabetes has been obstructed because the serum half-life of such peptides is quite short. For example, GLP-1(7-37) has a serum half-life of only 3 to 5 minutes. GLP-1(7-36) amide has a half-life of about 50 minutes when administered subcutaneously. Thus, these GLP molecules must be administered as a continuous infusion to achieve a prolonged effect [Gutniak M., et al., Diabetes Care 17:1039-1044 (1994)]. In the present invention, GLP-1's short half-life and the consequent need for continuous administration are not disadvantages because the patient is typically bed-ridden, in a cardiac intensive care unit, where fluids are continuously administered parenterally.

Brief Summary Text (14):

The present invention provides a method of reducing mortality and morbidity after

myocardial infarction, comprising administering a compound from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof, at a dose effective to normalize blood glucose, to a patient in need thereof.

Drawing Description Text (2):

FIG. 1 is a graph showing the effect of continuous infusion GLP-1 (7-36) amide on average blood glucose concentration (mM) {character pullout} in five NIDDM patients during the night. The graph also depicts the effect of continuous insulin infusion on average blood glucose concentration {character pullout} in the same five NIDDM patients, but on a different night.

Drawing Description Text (3):

FIG. 2 is a graph showing the effect of GLP-1 (7-36) amide infusion on average blood glucose concentration (mM) {character pullout} in five NIDDM patients when infused during the day, for three hours starting at the beginning of each of three meals. The graph also depicts the effect of subcutaneous injection of insulin on average blood glucose concentration {character pullout} in the same five NIDDM patients, but on a different day, and with injection shortly before each meal.

Detailed Description Text (2):

"GLP-1" means GLP-1(7-37). By custom in the art, the amino-terminus of GLP-1(7-37) has been assigned number 7 and the carboxy-terminus, number 37. The amino acid sequence of GLP-1(7-37) is well-known in the art, but is presented below for the reader's convenience:

Detailed Description Text (3):

A "GLP-1 analog" is defined as a molecule having one or more amino acid substitutions, deletions, inversions, or additions compared with GLP-1. GLP-1 analogs known in the art include, for example, GLP-1(7-34) and GLP-1(7-35), GLP-1(7-36), Gln.sup.9 -GLP-1(7-37), D-Gln.sup.9 -GLP-1(7-37), Thr.sup.16 -Lys.sup.18 -GLP-1(7-37), and Lys.sup.18 -GLP-1(7-37). Preferred GLP-1 analogs are GLP-1(7-34) and GLP-1(7-35), which are disclosed in U.S. Pat. No: 5,118,666, herein incorporated by reference, and also GLP-1(7-36), which are the biologically processed forms of GLP-1 having insulintropic properties. Other GLP-1 analogs are disclosed in U.S. Pat. No. 5,545,618 which is incorporated herein by reference.

Detailed Description Text (4):

A "GLP-1 derivative" is defined as a molecule having the amino acid sequence of GLP-1 or of a GLP-1 analog, but additionally having chemical modification of one or more of its amino acid side groups, .alpha.-carbon atoms, terminal amino group, or terminal carboxylic acid group. A chemical modification includes, but is not limited to, adding chemical moieties, creating new bonds, and removing chemical moieties. Modifications at amino acid side groups include, without limitation, acylation of lysine .epsilon.-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine. Modifications of the terminal amino include, without limitation, the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include, without limitation, the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. Lower alkyl is C.sub.1 -C.sub.4 alkyl. Furthermore, one or more side groups, or terminal groups, may be protected by protective groups known to the ordinarily-skilled protein chemist. The .alpha.-carbon of an amino acid may be mono- or SEQ ID NO: 6 dimethylated.

Detailed Description Text (5):

A preferred group of GLP-1 analogs and derivatives for use in the present invention is composed of molecules of the formula:

Detailed Description Text (7):

Numerous GLP-1 analogs and derivatives having an isoelectric point in this range have been disclosed and include, for example:

Detailed Description Text (8):

Another preferred group of active compounds for use in the present invention is disclosed in WO 91/11457, and consists essentially of GLP-1(7-34), GLP-1(7-35),

GLP-1(7-36), or GLP-1(7-37), or the amide form thereof, and pharmaceutically-acceptable salts thereof, having at least one modification selected from the group consisting of:

Detailed Description Text (14):

Because the enzyme, dipeptidyl-peptidase IV (DPP IV), may be responsible for the observed rapid in vivo inactivation of administered GLP-1, [see, e.g., Mentlein, R., et al., Eur. J. Biochem., 214:829-835 (1993)], administration of GLP-1 analogs and derivatives that are protected from the activity of DPP IV is preferred, and the administration of Gly.sup.8 -GLP-1(7-36)NH.sub.2, Val.sup.8 -GLP-1(7-37)OH, a-methyl-Ala.sup.8 -GLP-1(7-36)NH.sub.2, and Gly.sup.8 -Gln.sup.21 -GLP-1(7-37)OH, or pharmaceutically-acceptable salts thereof, is more preferred.

Detailed Description Text (25):

The use of GLP-1(7-36) amide, or a pharmaceutically-acceptable salt thereof, in the present invention is most highly preferred. The amino acid sequence of GLP-1(7-36) amide is:

Detailed Description Text (26):

Methods for preparing the active compound used in the present invention, namely, GLP-1, an GLP-1 analog, or a GLP-1 derivative used in the present invention are well-known, and are described in U.S. Pat. Nos. 5,118,666, 5,120,712, and 5,523,549, which are incorporated by reference.

Detailed Description Text (38):

a) isolating a natural DNA sequence encoding a GLP-1 molecule or constructing a synthetic or semi-synthetic DNA coding sequence for a GLP-1 molecule,

Detailed Description Text (41):

d) culturing the transformed host cell under conditions that will permit expression of a GLP-1 molecule, and

Detailed Description Text (42):

e) recovering and purifying the recombinantly produced GLP-1 molecule.

Detailed Description Text (44):

Synthetic genes, the in vitro or in vivo transcription and translation of which results in the production of a GLP-1 molecule, may be constructed by techniques well known in the art. Owing to the natural degeneracy of the genetic code, the skilled artisan will recognize that a sizable yet definite number of DNA sequences may be constructed, all of which encode GLP-1 molecules.

Detailed Description Text (46):

To express the amino acid portion of a compound used in the present invention, one inserts the engineered synthetic DNA sequence in any one of many appropriate recombinant DNA expression vectors through the use of appropriate restriction endonucleases. See generally Maniatis et al. (1989) Molecular Cloning; A Laboratory Manual, Cold Springs Harbor Laboratory Press, N.Y., Vol. 1-3. Restriction endonuclease cleavage sites are engineered into either end of the GLP-1 molecule-encoding DNA to facilitate isolation from, and integration into, amplification and expression vectors well-known in the art. The particular endonucleases employed will be dictated by the restriction endonuclease cleavage pattern of the parent expression vector employed. Restriction sites are chosen to properly orient the coding sequence with control sequences, thereby achieving proper in-frame reading and expression of the protein of interest. The coding sequence must be positioned to be in proper reading frame with the promoter and ribosome binding site of the expression vector, both of which are functional in the host cell in which the protein is to be expressed.

Detailed Description Text (58):

Alterations to a precursor GLP-1 or GLP-1 analog amino acid sequence, to produce a desired GLP-1 analog or GLP-1 derivative, are made by well-known methods: chemical modification, enzymatic modification, or a combination of chemical and enzymatic modification of GLP-1 precursors. The techniques of classical solution phase methods and semi-synthetic methods may also be useful for preparing the GLP-1 molecules used in the present invention. Methods for preparing the GLP-1 molecules of the present

invention are well known to an ordinarily skilled peptide chemist.

Detailed Description Text (60):

For example, an N-hydroxy-succinimide ester of octanoic acid can be added to the lysyl-epsilon amine using 50% acetonitrile in borate buffer. The peptide can be acylated either before or after the imidazolic group is added. Moreover, if the peptide is prepared recombinantly, acylation prior to enzymatic cleavage is possible. Also, the lysine in the GLP-1 derivative can be acylated as taught in W096-29342, which is incorporated herein by reference.

Detailed Description Text (61):

The existence and preparation of a multitude of protected, unprotected, and partially-protected, natural and unnatural, functional analogs and derivatives of GLP-1 (7-36)amide and GLP-1 (7-37) molecules have been described in the art [see, e.g., U.S. Pat. No. 5,120,712 and 5,118,666, which are herein incorporated by reference, and Orskov, C., et al., J. Biol. Chem., 264(22):12826-12829 (1989) and WO 91/11457 (Buckley, D. I., et al., published Aug. 8, 1991)].

Detailed Description Text (62):

Optionally, the amino and carboxy terminal amino acid residues of GLP-1 derivatives may be protected, or, optionally, only one of the termini is protected. Reactions for the formation and removal of such protecting groups are described in standard works including, for example, "Protective Groups in Organic Chemistry", Plenum Press, London and New York (1973); Green, T. H., "Protective Groups in Organic Synthesis", Wiley, New York (1981); and "The Peptides", Vol. I, Schroder and Lubke, Academic Press London and New York (1965). Representative amino-protecting groups include, for example, formyl, acetyl, isopropyl, butoxycarbonyl, fluorenylmethoxycarbonyl, carbobenzyloxy, and the like. Representative carboxy-protecting groups include, for example, benzyl ester, methyl ester, ethyl ester, t-butyl ester, p-nitro phenyl ester, and the like.

Detailed Description Text (63):

Carboxy-terminal, lower-alkyl-ester, GLP-1 derivatives used in the present invention are prepared by reacting the desired (C.sub.1 -C.sub.4) alkanol with the desired polypeptide in the presence of a catalytic acid such as hydrochloric acid. Appropriate conditions for such alkyl ester formation include a reaction temperature of about 50.degree. C. and reaction time of about 1 hour to about 3 hours. Similarly, alkyl ester derivatives of the Asp and/or Glu residues can be formed.

Detailed Description Text (65):

A pharmaceutically-acceptable salt form of GLP-1, of a GLP-1 analog, or of a GLP-1 derivative may be used in the present invention. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like. Preferred acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and, especially, hydrochloric acid.

Detailed Description Text (67):

A GLP-1, GLP-1 analog, or GLP-1 derivative used in the present invention may be formulated with one or more excipients before use in the present invention. For example, the active compound used in the present invention may be complexed with a divalent metal cation by well-known methods. Such metal cations include, for example, Zn.sup.++, Mn.sup.++, Fe.sup.++, Co.sup.++, Cd.sup.++, Ni.sup.++, and the like.

Detailed Description Text (79):

The dose of GLP-1, GLP-1 analog, or GLP-1 derivative effective to normalize a patient's blood glucose level will depend on a number of factors, among which are included, without limitation, the patient's sex, weight and age, the severity of inability to regulate blood glucose, the underlying causes of inability to regulate blood glucose, whether glucose, or another carbohydrate source, is simultaneously administered, the route of administration and bioavailability, the persistence in the body, the formulation, and the potency. Where administration is continuous, a suitable dosage rate is between 0.25 and 6 pmol/kg body weight/min, preferably from about 0.5 to about 1.2 pmol/kg/min. Where administration is intermittent, the dose per administration should take into account the interval between doses, the bioavailability of GLP-1, GLP-1 analog, or GLP-1 derivative, and the level needed to effect normal blood glucose. It is within the skill of the ordinary physician to titrate the dose and rate of administration of GLP-1, GLP-1 analog, or GLP-1 derivative to achieve the desired clinical result.

Detailed Description Text (82):

GLP-1 (7-36) amide was administered by a subcutaneous infusion at a dose rate of 1.2 pmol/kg/hr, for ten hours during the night, to five patients having non-insulin dependent diabetes (NIDDM). As a control, insulin was continuously infused in the same five patients, but on a different day than the GLP-1 (7-36) amide infusion. The rate of insulin infusion was adjusted every two hours to achieve optimum control, and to avoid hypoglycemia. As demonstrated by the data in Table 1, and in FIG. 1, subcutaneous infusion of GLP-1 (7-36) amide nearly normalized blood glucose without inducing hypoglycemia in any of the patients. The metabolic control with GLP-1 (7-36) amide was better than that achieved by insulin, and the average blood glucose level was lower for GLP-1 (7-36) amide treatment than for the control by a statistically significant amount at 23:00, 0:00, and at 1:00.

Detailed Description Text (84):

During the day, GLP-1 (7-36) amide was infused into five NIDDM patients for three hours during breakfast, lunch, and dinner. The infusion times were 7:30-10:30 (breakfast), 10:30-1:30 (lunch), and 4:30-7:30 (dinner), as indicated in FIG. 2. In a control experiment in the same five NIDDM patients conducted on a different day, insulin was injected subcutaneously just before the start of the meals, as indicated in FIG. 2. While GLP-1 was infused, the post-prandial glucose excursions observed with insulin injection were eliminated; and normal blood glucose levels were maintained. Immediately after terminating each GLP-1 (7-36) amide infusion, the blood glucose level increased significantly. No untoward side effects of GLP-1 (7-36) amide were observed. These data indicate that GLP-1 (7-36) amide infusion more effectively controls post-prandial glucose levels than insulin injection, and that the control is effective as long as GLP-1 (7-36) amide infusion is continued.

Detailed Description Paragraph Table (3):

GLP-1 (7-36)NH.sub.2 Gly.sup.8 -GLP-1 (7-36)NH.sub.2 Gln.sup.9 -GLP-1 (7-37)
D-Gln.sup.9 -GLP-1 (7-37) acetyl-Lys.sup.9 -GLP-1 (7-37) Thr.sup.9 -GLP-1 (7-37)
D-Thr.sup.9 -GLP-1 (7-37) Asn.sup.9 -GLP-1 (7-37) D-Asn.sup.9 -GLP-1 (7-37) Ser.sup.22
-Arg.sup.23 -Arg.sup.24 -Gln.sup.26 -GLP-1 (7-37) SEQ ID NO:6 Thr.sup.16 -Lys.sup.18
-GLP-1 (7-37) Lys.sup.18 -GLP-1 (7-37) Arg.sup.23 -GLP-1 (7-37) Arg.sup.24 -GLP-1
(7-37), and the like [see, e.g., WO 91/11457].

Detailed Description Paragraph Table (8):

TABLE 1 Average blood glucose levels for five NIDDM patients continuously infused for ten hours during the night with GLP-1 (7-36) amide. In a control study with the same patients on a different day, insulin was administered by continuous infusion. Insulin Infusion GLP-1 Infusion (Control) Average Average Blood Glucose Std. Error
Glucose Std. Error Hour (mM) (mM) (mM) (mM) 21:00 7.5 0.45 6.9 0.68 22:00 5.4 0.76 6.6
0.55 23:00 4.1 0.16 5.9 0.98 0:00 4.4 0.23 5.6 0.90 1:00 4.4 0.29 5.1 0.58 2:00 4.8
0.34 5.2 0.58 3:00 5.2 0.41 5.4 0.30 4:00 5.4 0.41 5.7 0.25 5:00 5.8 0.41 6.0 0.30
6:00 6.0 0.45 6.1 0.38 7:00 6.2 0.45 6.1 0.33

Detailed Description Paragraph Table (9):

TABLE 2 Average blood glucose levels for five NIDDM patients infused with GLP-1 (7-36) amide for three hours, beginning at the start of each meal. In a control study with the same patients on a different day, insulin was administered by subcutaneous

injection just before each meal. Meals began at 7:30, 10:30, and at 4:30. Insulin Subcutaneous GLP-1 Infusion Injection Average Average Blood Blood Glucose Std. Error Glucose Std. Error Hour (mM) (mM) (mM) (mM) 7:00 5.4 0.35 6.1 0.41 8:00 4.9 0.38 7.0 0.51 9:00 5.7 0.59 9.1 0.74 10:00 5.8 1.06 9.9 0.78 11:00 8.1 0.94 8.2 0.76 12:00 9.4 0.59 6.5 0.74 13:00 7.2 1.18 9.1 0.90 14:00 5.3 1.21 8.1 0.91 15:00 7.2 0.71 7.0 0.87 16:00 10.4 0.26 7.2 0.57 17:00 9.2 1.06 6.5 0.59 18:00 5.7 1.59 7.3 0.65 19:00 6.6 0.94 6.1 0.59 20:00 8.3 0.71 6.0 0.41 21:00 9.3 0.71 6.4 0.44

CLAIMS:

1. A method of reducing mortality and morbidity after myocardial infraction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof, at a dose effective to normalize blood glucose.

13. A method of reducing mortality and morbidity after myocardial infraction, comprising administering a GLP-1 analog to a patient in need thereof at a dose effective to normalize blood glucose, said GLP-1 analog being represented by the following structural formula:

R.sub.1 --X--Glu--Gly--Thr--Phe--Thr--Ser--Asp--Val--Ser--Ser--Tyr--Leu--Y--Gly--Gln--Ala--Ala--Lys--Z--Phe--Ile--Ala--Trp--Leu--Val--Lys--Gly--Arg--R.sub.2

and pharmaceutically-acceptable salts thereof,

wherein:

R.sub.1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, .beta.-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine;

X is selected from the group consisting of Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala;

Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

Z is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

R.sub.2 is selected from the group consisting of NH.sub.2, and Gly--OH;

provided that the GLP-1 analog has an isoelectric point in the range from about 6.0 to about 9.0 and further providing that when R.sub.1 is His, X is Ala, Y is Glu, and Z is Glu, R.sub.2 must be NH.sub.2.

14. A method of reducing mortality and morbidity after myocardial infraction in a patient with non-insulin dependent diabetes, said method comprising the step of administering to the patient, at a dose effective to normalize blood glucose, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof.

15. A method of reducing mortality and morbidity after myocardial infraction in a patient with non-insulin dependent diabetes, said method comprising the step of administering to the patient, at a dose effective to normalize blood glucose, a GLP-1 analog represented by the following structural formula:

R.sub.1 --X--Glu--Gly--Thr--Phe--Thr--Ser--Asp--Val--Ser--Ser--Tyr--Leu--Y--Gly--Gln--Ala--Ala--Lys--Z--Phe--Ile--Ala--Trp--Leu--Val--Lys--Gly--Arg--R.sub.2

and pharmaceutically-acceptable salts thereof,

wherein:

R.sub.1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, .beta.-hydroxy-histidine, homohistidine,

alpha-fluoromethyl-histidine, and alpha-methyl-histidine;

X is selected from the group consisting of Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala;

Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

Z is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

R.sub.2 is selected from the group consisting of NH.sub.2, and Gly--OH;

provided that the GLP-1 analog has an isoelectric point in the range from about 6.0 to about 9.0 and further providing that when R.sub.1 is His, X is Ala, Y is Glu, and Z is Glu, R.sub.2 must be NH.sub.2.

16. A method of reducing mortality and morbidity after myocardial infraction in a patient having a blood glucose level greater than 11 mmole/liter, said method comprising the step of administering to the patient, at a dose effective to normalize blood glucose, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof.

17. A method of reducing mortality and morbidity after myocardial infraction in a patient having a blood glucose level greater than 11 mmole/liter, said method comprising the step of administering to the patient, at a dose effective to normalize blood glucose, a GLP-1 analog represented by the following structural formula:

R.sub.1 --X--Glu--Gly--Thr--Phe--Thr--Ser--Asp--Val--Ser--Ser--Tyr--Leu--Y--Gly--Gln--Ala--Ala--Lys--Z--Phe--Ile--Ala--Trp--Leu--Val--Lys--Gly--Arg--R.sub.2

and pharmaceutically-acceptable salts thereof,

wherein:

R.sub.1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, .beta.-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine;

X is selected from the group consisting of Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala;

Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

Z is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

R.sub.2 is selected from the group consisting of NH.sub.2, and Gly--OH;

provided that the GLP-1 analog has an isoelectric point in the range from about 6.0 to about 9.0 and further providing that when R.sub.1 is His, X is Ala, Y is Glu, and Z is Glu, R.sub.2 must be NH.sub.2.

18. A method of reducing mortality and morbidity after myocardial infraction in a patient with abnormal glucose tolerance, said method comprising the step of administering to the patient, at a dose effective to normalize blood glucose, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof.

19. A method of reducing mortality and morbidity after myocardial infraction in a patient having abnormal glucose tolerance, said method comprising the step of a GLP-1 analog to the patient, at a dose effective to normalize blood glucose, a GLP-1 analog represented by the following structural formula:

R.sub.1 --X--Glu--Gly--Thr--Phe--Thr--Ser--Asp--Val--Ser--Ser--Tyr--Leu--Y--Gly--Gln--Ala--Ala--Lys--Z--Phe--Ile--Ala--Trp--Leu--Val--Lys--Gly--Arg--R.sub.2

and pharmaceutically-acceptable salts thereof,

wherein:

R.sub.1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, .beta.-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine;

X is selected from the group consisting of Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala;

Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

Z is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly;

R.sub.2 is selected from the group consisting of NH.sub.2, and Gly--OH;

provided that the GLP-1 analog has an isoelectric point in the range from about 6.0 to about 9.0 and further providing that when R.sub.1 is His, X is Ala, Y is Glu, and Z is Glu, R.sub.2 must be NH.sub.2.

WEST**Freeform Search****Database:**

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

14 and 15

Display: **Documents in Display Format:** **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show 8 Numbers

Edit 8 Numbers

Preferences

Cases

Search History**DATE:** Friday, October 11, 2002 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L6</u>	14 and 15	6	<u>L6</u>
<u>L5</u>	GLP-1	478	<u>L5</u>
<u>L4</u>	diabetic cardiomyopathy	63	<u>L4</u>
<u>L3</u>	11 and 12	15	<u>L3</u>
<u>L2</u>	cancer	106491	<u>L2</u>
<u>L1</u>	echinacea purpurea	114	<u>L1</u>

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 15:34:48 ON 11 OCT 2002)

FILE 'CA, BIOSIS, MEDLINE' ENTERED AT 15:35:01 ON 11 OCT 2002

L1 1065 S DIABETIC CARDIOMYOPATHY?

L2 3549 S GLP-1

L3 1 S L1 AND L2

=>